# OnCo record columbus (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/columbus/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "columbus", "NCT01909453" ;
  schema:name "COLUMBUS"@en ;
  schema:description "COLUMBUS tested encorafenib-binimetinib, the third BRAF/MEK doublet, which has the longest median survival of the class and less fever than dabrafenib-trametinib."@en ;
  schema:url <https://onco.cc/trials/columbus/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01909453>, <https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30142-6/fulltext> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2013-09-12" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/vemurafenib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:people <https://onco.cc/people/paolo-ascierto/>, <https://onco.cc/people/reinhard-dummer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-columbus-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-columbus-lancet-oncol-2018-update/> .